Yakkang Biotech (688046.SH) posted an advance increase. Net profit for the first half year is expected to be 104 million yuan to 114 million yuan, an increase of 46.67% to 60.78% over the previous year

According to Zhitong Finance App News, Yakkang Biotech (688046.SH) released its 2026 semi-annual performance forecast. The company expects to achieve net profit of 104 million yuan to 114 million yuan in the 2026 semi-year, an increase of 46.67% to 60.78% over the previous year. Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss for the first half year of 2026 is expected to be 92 million yuan to 100 million yuan, an increase of 46.20% to 58.92% over the previous year.

During the reporting period, the company anchored the core strategy of internationalization and innovation. On the one hand, it accelerated the layout and improvement of sales networks in overseas markets, and on the other hand, continued to increase investment in R&D resources, and its leading edge in technology and products was further consolidated and strengthened. The company relies on a mature general underlying technology system and forward-looking layout of emerging technology platforms such as all-human antibody platforms and microbiome research and development platforms to accelerate the implementation and transformation of R&D results and build new growth points for the company's medium- to long-term sustainable growth.

During the reporting period, the company's net profit attributable to the owner of the parent company and net profit growth attributable to the owner of the parent company mainly came from the following aspects: First, on the overseas market side, the company continued to improve the localized sales and service system, and has now completed market coverage in the three core regions of North America, Europe and Asia Pacific. The scale of cooperative customers has been steadily expanding, and brand recognition has continued to increase, driving high gross profit revenue in the overseas sector to maintain a relatively rapid growth trend; Second, the domestic market side benefited from the recovery in the biomedical industry, the desire to invest in R&D by downstream industrial customers. Maintaining the economy, the company's functional efficacy business segment continued to gain strength, and revenue accelerated markedly; third, on the cost side, the capacity utilization rate of newly built production and operation facilities in various parts of the company continued to rise, and scale effects were gradually released, driving a steady increase in product gross margin. At the same time, the company continued to improve the full-link refined cost management and control system, continued to optimize operational efficiency, and the overall cost rate for the period decreased compared to the same period last year.